1 / 47

Case #1

Case #1. Alexa Simon MSIV September 19, 2007 UNC Infectious Disease. CC: Nausea vomiting, fever.

nora
Download Presentation

Case #1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Case #1 • Alexa Simon MSIV • September 19, 2007 • UNC Infectious Disease

  2. CC: Nausea vomiting, fever • HPI: 56 y/0 AAF with history significant for ovarian cancer stage IIIC with a complicated surgical history including debulking surgery in 2005, ileocecal resection, and recent repair of enterocutaneous fistula presented to Johnston Memorial with acute onset of nausea, vomiting, fever and abdominal pain.

  3. HPI cont…. • At JM she was found on CT scan to have fluid collection in the anterior subcutaneous tissue. • She was started on Zosyn • Patient was transferred to Gyn/Onc at UNC and started on Ceftazidine and Flagyl.

  4. HPI cont…. • She progressively became more hypotension with increasing 02 requirements: • Became obtunded and ID consult team was paged. • The Ob/gyn resident ended phone call to ID saying “I need to go intubate the patient.”

  5. Tumor History • Prior to 2005 was healthy • 9/2005: Presents with abdominal pain • CT with massive ascites and 2 large adnexal masses • CA-125>300 • 9/29/2005: Ex-laporatomy BSO with iliocecal resection, • Re-anastomosis omentectomy • Suboptimal debulking mass • PE with attempted VIR for embolectomy of saddle embolus • Multiple MIs • TPN dependence begins • 12/2005: Chemotherapy began with Taxol • 7/2007: Repair enterocutaneous fistula

  6. Infection History • 10/2006: Candida albicans and coagulase negative staphylococcal infection at port site • Rx: Fluconazole and daptomycin for 2 wks • 11/2006: Candida parapsilosis fungemia • Rx: Capsofungin with 8 wks • 1/2007: Coagulase negative staphylococcal and ampicillin sensitive enterococcal bacteremia • Rx: Daptomycin • 3/07: Coagulase negative staphylococcal bacteremia • Rx: Daptomycin • 7/2007 coag negative staph line infection and UTIs with enterococci and candida • Rx: Linezolid and fluconazole

  7. Additional History • SH: • Patient denies alcohol, tobacco, drugs • Family History • Mother had ovarian cancer • Father had prostate cancer • ROS: unobtainable due to intubation and sedation

  8. Meds Ceftazidine 2g IV q12 Flagyl 500mg q12 Linezolid 600mg q12 Micafungin 100 mg IV QD Dopamine GGT Morphine PRN Benadryl PRN Phenergan PRN Zofran PRN Allergies Zosyn: Rash Ace Inhibitors: Rash Vancomycin: Rash PCN: Rash Zofran: Rash Additional History

  9. Physical Exam • Vitals: Tmax 36.8/Tc: 35.9 BP:110/58 P:87 CVP:14-17 • Vent: SIMV PS:10 PEEP:5 FIO2%:40 TV 600 Rate 16 • General: Intubated, withdraws from pain 6-7/T • HEENT: Icteric, PERRLA, no LAD • CV: RRR 2/6 holosystolic murmur, non radiating on left sternal border; no rubs or gallops • Lungs: Crackles Bilaterally at bases • Skin: jaundiced, no rash or bruising noted • Abdomen: tender throughout, no rebound, hypoactive bowel sounds; multiple surgical scars, with palpable subcutaneous midline mass (not fluctuant) • No hepatosplenomegaly appreciated • Extremities: 1+ pitting edema bilaterally

  10. 71 181 Labs: 9.2 139 112 31 • Ca:7.4 Mg:1.9 Phos:4.6 • GGT:122 • Differential: • ANC: 18.0↑ • ALC:0.8 • AMC: 0.8 • AEC:0.2 • ABC: 0 20.7 51 14 1.5 3.1 27.5 6.2 2.2 21.6 20.4 84 74

  11. Radiology • RUQ US: • Lack visualized flow in portal veins/SMV, some echogenic material in portal veins concerning for clot • Hepatomegaly • New extrahepatic biliary ductal dilations

  12. CT Adomen/ Pelvis

  13. Radiology • CTA Abdomen: • Fluid collections contain focal area of gas with density within the soft tissues overlaying a anterior abdominal wall may represent abscess • Increase in the size of multiple high density lesions seen in the liver, which contain calcifications. • Low density fluid in pelvis collection with in abdomen c/w ascites • Stable Left pleural effusion

  14. DISCUSSION………..

  15. Her Results: Microbiology: Urine Culture: gram positive cocci in chains Blood Culture (peripheral and central line): GPCs in chains and GPRs Abdominal abscess: GPCs in chains TTE: Left Ventricle: hyperdynamic EF: 65-70% Mitral Valve: thickened with mild prolapse, moderate regurgitation Aortic Valve: trileaflet with mild thickening Right Ventricle: normal Tricupsid Valve: mild thickening with mobile echo from the atrial surface consistent with degenerative, disease and vegetation, with mild regurgitation Pulmonary Valve: not well imagine

  16. Infectious Disease Diagnosis • Bacteremia: • Enterococci (ampicillin sensitive, but gentamicin R) • Bacillus cereus • Endocarditis of the tricuspid valve • Antibiotics used: Imepenem/cilastin and daptomycin used to treat for 12 weeks

  17. B. cereus now…

  18. Bacillus cereus • Commonly found in soil, inanimate objects, and mucus membranes healthy people • Gram positive motile rods with paracentral spores • Taxonomy of 3 groups: large cell subgroup, small cell, mixed • Large group is B. anthracis and cereus • They differ by fewer 9 nucleotides

  19. Bacillus cereus cont’d… • Grows on blood agar as large flat, granular, ground glass, beta-hemolytic • Grows aerobically and a facultative anaerobe • Contains catalase, hemolysins, beta-lactamases, oxididase • Ferments glucose, maltose, sucrose, trehalose • Does not ferment lactose, xylose, mannitol • Resistant to heat • Motile

  20. Bacillus cereus Toxins • Enterotoxin- can be necrotizing • Emetic toxin- mitochondrial toxin • Inhibits mitochondrial fatty-acid oxidation • Can cause liver failure • Phospholipases- release lysozyme enzymes (like alpha toxin c. perfringens) • Proteases • Hemolysins-causing cell lysis of leukocytes and macrophages • Beta-lactamases thus resistant to most PCNs

  21. Bacillus cereus Infections • 1: Local (burns, trauma, post op, fulminant eye infections) • 2: Bacteremia/septicemia • 3: CNS • 4: Respiratory infection • 5: Endocarditis, pericarditis • 6: Food poisoning, toxin induced • Increase in non-food poisoning in IVDU, neonates, malignancy, AIDs, prosthetic parts • Most common form is GI intoxication from spores by enterotoxins

  22. Food-Poisoning • Occurs 6-8hrs after ingesting B. cereus toxins • Patients typically have significant emesis and less frequently diarrhea • Enterotoxins : hemolysin, non-hemolytic enterotoxin, enterotoxin T, and cytotoxin K • Emetic toxin • No fevers because not systemic disease • Commonly isolated from reheated foods

  23. Endophthalmitis • 5/10,000 hospital patients • 60% occur after intraocular surgery • Often due to transient bacterial contamination by conjuctival flora • 4-13% after penetrating trauma • Once inoculated bacillus spreads through out whole eye • If motile strain <12 hours to detect inflammatory reaction in the eye • Symptoms: pain “ache”, redness, blurry vision, ring corneal infiltrate • Loss retinal function in 18hours if fully virulent (pclR gene and motile) • High morbidity with loss of vision in infected eye • Phospholipases toxins responsible for the destructions • Treatment is injection of antibiotics into the vitreous and vitrectomy, along with systemic antibiotics.

  24. 5 year Review of Cleveland Hospitals From: 1981-1986 • 38 patients with significant Bacillus infections: • 78.9% bacteremia • 1/3 IVDU or had indwelling catheters, 4 had cancer • 30% IVDU • 7.9% endopthalmitis • 1.8% Endocarditis (only with IVDU) • Osteomyelitis • Visceral infection- significant morbidity • 1 pneumonia and1 necrotizing fasciitis after trauma Medicine (Baltimore) 1987;66(3):218-23.

  25. 5 year Review continued… • Intravascular device (pacemaker, central line) is a cause of the nosocomial bacillus bacteremia • 4/38 patients improved after removal intravascular catheter with out antibiotics • Endocarditis rare phenomenon with B. Cereus • Overall patients with primary bacteremia recovered quicker and had less morbidity then patient with a localized infection Medicine (Baltimore) 1987;66(3):218-23.

  26. Bacillus spp. Among hospitalized patients with Haematological malignancies • 3.4% bacteremic with bacillus spp. • Most only presented with fever • Few cases of pneumonia, GI/Hepatic symptoms • Patients that are granulocytopenic are at risk for opportunistic infections with bacillus • Many species can effect neutropenic patients which in clude B. licheniformis, B. cereus, B. pumilus • All patient were bacteremic, only few had pneumonias, endocarditis, or localized infections Journal of Hospital Infections 2006.;64(2):169-76.

  27. Pseudo Epidemics • Outbreaks have been seen in dialysis units, ICUs, neonatal ICUs • Bacillus spores are sticky • Non-sterile cotton wool • Laundered linens including gowns, sheets • Ventilation systems • Dressings • Hands • Dairy plants- filling machines • Korean dried red pepper

  28. Contaminated Transfusions • Platelet transfusions: contaminated 0.08-0.7 % • Stored at room temperatures, thus longer storage time increase risk of contamination • Possible contaminants: dipthroid rods, coagulase negative staph, B. cereus, E. cloacae, E. coli, P. aeruginosa • Most cases deteriorated with minutes of transfusion • Leading to hospital outbreaks of infections • More common with patients with hematological malignancy • Second to transfusions or long term indwelling catheters • Blood transfusions no data seen

  29. Treatment • B. Cereus inherently resistant to most beta-lactams • Antibiotics known to work: • Imipenem • Clindamycin • In vitro activities of antibiotics on Bacillus spp and Spores • Aminoglycosides: MIC 2-0.5 • Doxycycline: MIC 0.5 • Vancomycin: MIC 1 • Erythromycin: MIC>16 • Ciprofloxacin: MIC 0.25 • Daptomycin: MIC 1 Journal of Clinical Microbiology 2006;44(10):3814-18

  30. References • te Boekhorst PA, et al. Clinical significance of bacteriologic screening in platelet concentrates. Transfusion 2005;45(4):514-19. • Drobniewski FA. Bacillus cereus and related species. Clinical microbiology reviews 1993;6(4):324-38. • Sliman R, et al. Serious infections caused by bacillus species. Medicine (Baltimore)1987;66(3):218-23. • Rotman B, Cote MA. Application of real-time biosensor to detect bacteria in platelet concentrates. Biochemical and biophysical research communications 2003;300(1):197-200. • Yomtovian R, et al. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterial contaminated platelets. Transfusion 1993;33(11):902-9. • Guinebretiere MK, et al. Enterotoxigenic profiles of food-poisoning and food-borne bacillus cereus strains. Journal of Clinical Microbiology 2002;40(8):3053-56.

  31. References (cont’d.) • Callegan M, et al. Bacillus endophthalmitis: Role of bacterial toxins and motility during infections.Investigative Ophthalmology and Visual Science 2005;46(9):3233-8. • Citron DM, Appleman MD. In vitro activities of daptomycin, ciprofloxacin, and other antimicrobial agents against the cells and spores of clinical isolates of bacillus species. Journal of Clinical Microbiology2006;44(10):3814-8. • Mahler H, et al. Fulminant liver failure in association with the emetic toxin of bacillus cereus. NEJM 1997;336(16):1142-8. • Ozkocaman V, et al. Bacillus spp. among hospitalized patients with haematological malignancies: clinical features, epidemics and outcomes. Journal of Hospital Infections 2006;64(2):169-76.

  32. Search PubMed • Bacillus Cereus Bacteremia • Case Reports • Reviews • Differential Diagnosis • Drug Therapy

More Related